Arkolith/Insider Trading/ZNTL/Form 4

Skvarka Jan

DirectorZentalis Pharmaceuticals, Inc. (ZNTL) · full profile →Form 4 · filed Feb 4, 2025
Net Buying
Open-Market Buys
$103K
Open-Market Sells
$0
Net Open-Market Flow
$103K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 31, 2025Buy(P)60K$1.72$103K150K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001725160-25-000030) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML